{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:29:47Z","timestamp":1780410587800,"version":"3.54.1"},"reference-count":62,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health\u2019s National Institute of Allergy and Infectious Diseases","award":["R01AI152772"],"award-info":[{"award-number":["R01AI152772"]}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32FP30_207285, 324730_207957"],"award-info":[{"award-number":["32FP30_207285, 324730_207957"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>HIV drug resistance poses a challenge to the United Nation\u2019s goal of ending the HIV\/AIDS epidemic. The integrase strand transfer inhibitor (InSTI) dolutegravir, which has a higher resistance barrier, was endorsed by the WHO in 2019 for first-line, second-line and third-line antiretroviral therapy (ART). This multiplicity of roles of dolutegravir in ART may facilitate the emergence of dolutegravir resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Nested within the International epidemiology Databases to Evaluate AIDS (IeDEA), DTG RESIST is a multicentre study of adults and adolescents living with HIV in sub-Saharan Africa, Asia, and South and Central America who experienced virological failure on dolutegravir-based ART. At the time of virological failure, whole blood will be collected and processed to prepare plasma or dried blood spots. Laboratories in Durban, Mexico City and Bangkok will perform genotyping. Analyses will focus on (1) individuals who experienced virological failure on dolutegravir and (2) those who started or switched to such a regimen and were at risk of virological failure. For population (1), the outcome will be any InSTI drug resistance mutations, and for population (2) virological failure is defined as a viral load &gt;1000 copies\/mL. Phenotypic testing will focus on non-B subtype viruses with major InSTI resistance mutations. Bayesian evolutionary models will explore and predict treatment failure genotypes. The study will have intermediate statistical power to detect differences in resistance mutation prevalence between major HIV-1 subtypes; ample power to identify risk factors for virological failure and limited power for analysing factors associated with individual InSTI drug resistance mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The research protocol was approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal, South Africa and the Ethics Committee of the Canton of Bern, Switzerland. All sites participate in International epidemiology Databases to Evaluate AIDS and have obtained ethics approval from their local ethics committee to collect additional data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06285110\">NCT06285110<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-085819","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:52:29Z","timestamp":1724287949000},"page":"e085819","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST)"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct06285110","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-5132","authenticated-orcid":false,"given":"Matthias","family":"Egger","sequence":"first","affiliation":[{"name":"Institute of Social & Preventive Medicine, University of Bern, Bern, Switzerland"},{"name":"Centre for Infectious Disease Epidemiology and Research, University of Cape Town Faculty of Health Sciences, Cape Town, Western Cape, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Sauermann","sequence":"additional","affiliation":[{"name":"Institute of Social & Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Loosli","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland"},{"name":"Institute of Medical Virology, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hossmann","sequence":"additional","affiliation":[{"name":"Institute of Social & Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Riedo","sequence":"additional","affiliation":[{"name":"Institute of Social & Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niko","family":"Beerenwinkel","sequence":"additional","affiliation":[{"name":"Department of Biosystems Science and Engineering, ETH Z\u00fcrich, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Jaquet","sequence":"additional","affiliation":[{"name":"National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, University of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Minga","sequence":"additional","affiliation":[{"name":"Centre M\u00e9dical de Suivi des Donneurs de Sang, Abidjan, C\u00f4te d'Ivoire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Ross","sequence":"additional","affiliation":[{"name":"TREAT Asia\/amfAR \u2013 The Foundation for AIDS Research, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Giandhari","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D","family":"Kouyos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland"},{"name":"Institute of Medical Virology, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lessells","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa"},{"name":"Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"2025121510111736000_14.8.e085819.1","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","article-title":"HIV drug resistance in low-income and middle-income countries","volume":"5","author":"Hamers","year":"2018","journal-title":"Lancet HIV"},{"key":"2025121510111736000_14.8.e085819.2","unstructured":"World Health Organization . WHO HIV drug resistance report 2017. Geneva: World Health Organization, 2017."},{"key":"2025121510111736000_14.8.e085819.3","unstructured":"World Health Organization . WHO HIV drug resistance report 2019. Geneva: World Health Organization, 2019."},{"key":"2025121510111736000_14.8.e085819.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00536-8"},{"key":"2025121510111736000_14.8.e085819.5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025121510111736000_14.8.e085819.6","unstructured":"World Health Organization . WHO Global action plan on HIV drug resistance 2017\u20132021. Geneva: World Health Organization, 2017."},{"key":"2025121510111736000_14.8.e085819.7","unstructured":"World Health Organization . WHO guidelines on the public health response to pretreatment HIV drug resistance. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2016. 2nd edn. Geneva: World Health Organization, 2017."},{"key":"2025121510111736000_14.8.e085819.8","unstructured":"World Health Organization . Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization, 2019."},{"key":"2025121510111736000_14.8.e085819.9","unstructured":"WHO Global HIV Programme . WHO HIV policy adoption and implementation status in Countries. Geneva, Switzerland: World Health Organizaiton, 2022."},{"key":"2025121510111736000_14.8.e085819.10","first-page":"56","article-title":"Genetic barrier to resistance for dolutegravir","volume":"17","author":"Llibre","year":"2015","journal-title":"AIDS Rev"},{"key":"2025121510111736000_14.8.e085819.11","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0093-2"},{"key":"2025121510111736000_14.8.e085819.12","doi-asserted-by":"crossref","unstructured":"Cevik M , Orkin C , Sax PE . Emergent resistance to dolutegravir among INSTI-Na\u00efve patients on first-line or second-line antiretroviral therapy: a review of published cases. Open Forum Infect Dis 2020;7. doi:10.1093\/ofid\/ofaa202","DOI":"10.1093\/ofid\/ofaa202"},{"key":"2025121510111736000_14.8.e085819.13","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy332","article-title":"Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: rare but possible","volume":"6","author":"Pena","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025121510111736000_14.8.e085819.14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw165"},{"key":"2025121510111736000_14.8.e085819.15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00228-X"},{"key":"2025121510111736000_14.8.e085819.16","doi-asserted-by":"crossref","DOI":"10.3390\/v14040729","article-title":"Pre-treatment integrase inhibitor resistance and natural polymorphisms among HIV-1 subtype C infected patients in Ethiopia","volume":"14","author":"Arimide","year":"2022","journal-title":"Viruses"},{"key":"2025121510111736000_14.8.e085819.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035246","article-title":"International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019","volume":"10","author":"Chammartin","year":"2020","journal-title":"BMJ Open"},{"key":"2025121510111736000_14.8.e085819.18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dym073"},{"key":"2025121510111736000_14.8.e085819.19","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyl286"},{"key":"2025121510111736000_14.8.e085819.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2025121510111736000_14.8.e085819.21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/135965350801302S05","article-title":"World Health Organization\/HIVResNet drug resistance laboratory strategy","volume":"13","author":"Bertagnolio","year":"2008","journal-title":"Antivir Ther (Lond)"},{"key":"2025121510111736000_14.8.e085819.22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix386"},{"key":"2025121510111736000_14.8.e085819.23","article-title":"An affordable HIV-1 drug resistance monitoring method for resource limited settings","volume":"85","author":"Manasa","year":"2014","journal-title":"J Vis Exp"},{"key":"2025121510111736000_14.8.e085819.24","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","article-title":"Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey","volume":"3","author":"\u00c1vila-R\u00edos","year":"2016","journal-title":"Lancet HIV"},{"key":"2025121510111736000_14.8.e085819.25","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku499"},{"key":"2025121510111736000_14.8.e085819.26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy881"},{"key":"2025121510111736000_14.8.e085819.27","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01516-12"},{"key":"2025121510111736000_14.8.e085819.28","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz256"},{"key":"2025121510111736000_14.8.e085819.29","unstructured":"Monogram Biosciences . PhenoSense Integrase, Available: https:\/\/monogrambio.labcorp.com\/resources\/phenotyping\/phenosense-integrase"},{"key":"2025121510111736000_14.8.e085819.30","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"2025121510111736000_14.8.e085819.31","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1203"},{"key":"2025121510111736000_14.8.e085819.32","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/S2352-3018(15)00087-9","article-title":"Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis","volume":"2","author":"Haas","year":"2015","journal-title":"Lancet HIV"},{"key":"2025121510111736000_14.8.e085819.33","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328349822f"},{"key":"2025121510111736000_14.8.e085819.34","doi-asserted-by":"crossref","unstructured":"Riley RD , Croft P , Windt D van der . Prognosis research in healthcare: concepts, methods, and impact. Oxford, New York: Oxford University Press, 2019.","DOI":"10.1093\/med\/9780198796619.001.0001"},{"key":"2025121510111736000_14.8.e085819.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"2025121510111736000_14.8.e085819.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003203","article-title":"The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients","volume":"9","author":"Beerenwinkel","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"2025121510111736000_14.8.e085819.37","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxv019"},{"key":"2025121510111736000_14.8.e085819.38","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw459"},{"key":"2025121510111736000_14.8.e085819.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163746","article-title":"Genome-wide association study of HIV whole genome sequences validated using drug resistance","volume":"11","author":"Power","year":"2016","journal-title":"PLoS ONE"},{"key":"2025121510111736000_14.8.e085819.40","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2016.132"},{"key":"2025121510111736000_14.8.e085819.41","doi-asserted-by":"publisher","DOI":"10.1086\/519795"},{"key":"2025121510111736000_14.8.e085819.42","unstructured":"NCSS, LLC . PASS 2024 power analysis & sample size. Kaysville, Utah, USA, 2015. Available: https:\/\/www.ncss.com\/software\/pass\/"},{"key":"2025121510111736000_14.8.e085819.43","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S"},{"key":"2025121510111736000_14.8.e085819.44","doi-asserted-by":"publisher","DOI":"10.1177\/0962280214558972"},{"key":"2025121510111736000_14.8.e085819.45","unstructured":"World Health Organization . WHO update of recommendations on first- and second-line antiretroviral regimens. Geneva: World Health Organization, 2019."},{"key":"2025121510111736000_14.8.e085819.46","unstructured":"World Health Organization . WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization, 2016."},{"key":"2025121510111736000_14.8.e085819.47","unstructured":"World Health Organization . WHO Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Interim guidance. Geneva: World Health Organization, 2018."},{"key":"2025121510111736000_14.8.e085819.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69158-7"},{"key":"2025121510111736000_14.8.e085819.49","doi-asserted-by":"crossref","first-page":"S801","DOI":"10.1093\/infdis\/jix402","article-title":"The World Health Organization\u2019s response to emerging human immunodeficiency virus drug resistance and a call for global action","volume":"216","author":"Bertagnolio","year":"2017","journal-title":"J Infect Dis"},{"key":"2025121510111736000_14.8.e085819.50","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyr080"},{"key":"2025121510111736000_14.8.e085819.51","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.17.1.19045","article-title":"Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration","volume":"17","author":"Duda","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2025121510111736000_14.8.e085819.52","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25101","article-title":"Screening and management of mental health and substance use disorders in HIV treatment settings in low- and middle-income countries within the global IeDEA consortium","volume":"21","author":"Parcesepe","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"2025121510111736000_14.8.e085819.53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002822","article-title":"Changes in rapid HIV treatment initiation after national \u201ctreat all\u201d policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis","volume":"16","author":"Tymejczyk","year":"2019","journal-title":"PLOS Med"},{"key":"2025121510111736000_14.8.e085819.54","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283121ca9"},{"key":"2025121510111736000_14.8.e085819.55","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix915"},{"key":"2025121510111736000_14.8.e085819.56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001111","article-title":"Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America","volume":"8","author":"Chi","year":"2011","journal-title":"PLoS Med"},{"key":"2025121510111736000_14.8.e085819.57","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30673-X"},{"key":"2025121510111736000_14.8.e085819.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2011.12.001"},{"key":"2025121510111736000_14.8.e085819.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.10.026"},{"key":"2025121510111736000_14.8.e085819.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.08.006"},{"key":"2025121510111736000_14.8.e085819.61","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ102"},{"key":"2025121510111736000_14.8.e085819.62","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir669"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-085819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:11:24Z","timestamp":1765822284000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-085819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,21]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjopen-2024-085819"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-085819","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.23.24307850","asserted-by":"object"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}